Effectiveness of Ceftazidime-Avibactam versus Colistin against Carbapenem-Resistant Enterobacteriaceae- A Retrospective Study
Publish place: Infection Epidemiology and Microbiology، Vol: 10، Issue: 2
Publish Year: 1403
نوع سند: مقاله ژورنالی
زبان: English
View: 25
This Paper With 11 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IEM-10-2_002
تاریخ نمایه سازی: 29 خرداد 1403
Abstract:
Background: This study compared the efficacy of ceftazidime-avibactam (CAZ-AVI) with colistin for treating carbapenem-resistant Enterobacteriaceae (CRE) infections.
Materials & Methods: This retrospective study included ۱۲۰ patients with a confirmed CRE infection and information on causative bacteria and their susceptibility pattern. Patients were divided into two groups: those receiving CAZ-AVI and/or aztreonam (n=۵۳) and those receiving colistin (n=۶۷) for at least seven days. The colistin group was further subdivided into those who switched to CAZ-AVI due to poor outcomes. Patient data, including demographics, clinical history, microbiological data, Charlson comorbidity index, and outcomes, were collected and analyzed. Mann-Whitney U, Chi-square, and Fisher’s exact tests were used to compare the groups. P< .۰۵ was considered statistically significant.
Findings: The findings revealed comparable clinical characteristics, there were no major differences in mean duration of hospitalization, intensive care unit (ICU) admission, and Charlson scores between the two groups. The CAZ-AVI group required a significantly longer duration of antibiotic treatment (p= .۰۱۸) and more source control measures (p= .۰۰۹). Klebsiella pneumoniae was the predominant causative pathogen in both groups, with NDM and OXA۴۸ carbapenem resistance genes being the most common. Toxicity (p= .۰۰۱) and mortality (p= .۰۴۹) were significantly higher in the colistin group. Higher improvement was observed among the CAZ-AVI group and higher mortality among the colistin group (p= .۰۴۹).
Conclusion: CAZ-AVI could serve as an alternative to colistin for treating CRE infections. Further research is necessary to confirm these findings and provide evidence-based guidelines for managing CRE infections in India.
Keywords:
Authors
Nilaa Gopikrishnan
Junior Resident, PSG Institute of Medical Sciences & Research, Coimbatore, Tamil Nadu
Krishna S Nair
Department Of General Medicine, PSG Institute of Medical Sciences & Research, Coimbatore, Tamil Nadu
Elsa Mathew
Clinical Pharmacist, Department Of General Medicine, PSG Institute of Medical Sciences Research, Coimbatore, Tamil Nadu
Denesh Narasimhan
Professor, Department Of General Medicine, PSG Institute of Medical Sciences Research, Coimbatore, Tamil Nadu
Murali Alagesan
Professor, Department Of General Medicine, PSG Institute of Medical Sciences Research, Coimbatore, Tamil Nadu
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :